Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children.
about
Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemiasHydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.Technology Access and Smartphone App Preferences for Medication Adherence in Adolescents and Young Adults With Sickle Cell Disease.Physical activity level and performance in the six-minute walk test of children and adolescents with sickle cell anemia.Hydroxyurea is associated with lower costs of care of young children with sickle cell anemiaDo difficulties in swallowing medication impede the use of hydroxyurea in children?The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell miceHydroxyurea down-regulates BCL11A, KLF-1 and MYB through miRNA-mediated actions to induce γ-globin expression: implications for new therapeutic approaches of sickle cell diseaseA systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell diseaseEmerging science of hydroxyurea therapy for pediatric sickle cell disease.Examining Biopsychosocial Factors in Relation to Multiple Pain Features in Pediatric Sickle Cell Disease.Endothelin receptor antagonists in sickle cell disease: A promising new therapeutic approach.Emerging point-of-care technologies for sickle cell disease screening and monitoring.Adherence to hydroxyurea medication by children with sickle cell disease (SCD) using an electronic device: a feasibility study.Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: impact of national guidelines.Cistanche deserticola decoction alleviates the testicular toxicity induced by hydroxyurea in male mice.Perception of pain among pediatric patients with sickle cell pain crisis.Efficacy of fixed low dose hydroxyurea in Indian children with sickle cell anemia: a single centre experience.Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey.Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know.Randomized feasibility trial to improve hydroxyurea adherence in youth ages 10-18 years through community health workers: The HABIT study.Therapeutic red blood cell exchange in a child with sickle cell anaemia using the Spectra Optia® apheresis system.
P2860
Q24187646-9EFF8DCB-6054-4908-9FCC-28F5D33646A4Q33436115-A89E192D-2BE0-4422-B8A8-F3D3B8E4A535Q33447034-ACEB4273-FB36-4DEF-B365-D70F7A76CD76Q33759029-140BC29E-0BB0-435D-91EE-E08BFB79B6BDQ33819687-A5FDF98A-5EE2-4AB4-8D5E-D80648364C4FQ34285113-DC51822E-48F3-4ED4-8F4B-CEA4135A8FD7Q35859235-AA82FB9D-0E5E-4FC5-9B67-67196175150AQ36777717-624FC7CE-791A-412D-A220-9F35E245769BQ36792555-DF79F61A-7562-4934-B96F-2E5D54A38014Q38164192-7AD91FDD-05BB-459D-92C0-BCB585433A00Q38730706-4AAFD68A-5E16-41AE-8C40-968C33535C24Q38799393-E976EE22-F6BD-4900-B9AE-192C4FAECE5DQ38804432-9B32FA2A-4446-45EE-8EE5-18609CCE0250Q39736284-3C3290B2-184D-4192-964D-CEF8B1B57BD3Q40721306-1D86EA27-FEF5-42A5-BC1A-DEE78C33D28FQ42140269-9E8FC8DD-AED5-4A9F-90D0-09D5AE557243Q43426236-89523218-5479-443D-B70D-0B17487E85A5Q46075053-CEF95274-185E-4D97-86E3-26B3CF461B3DQ46853675-51342F2A-E624-41E2-8140-A22618E8B9F6Q47955242-FCF7EF47-4468-4A7A-8528-A8E40063495DQ48232192-ABCCD175-054C-4218-8E17-E74C1648E953Q50476827-0DF9526B-2D88-4412-A64F-1B2C13E923CF
P2860
Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Hydroxyurea for the treatment ...... y, and management in children.
@ast
Hydroxyurea for the treatment ...... y, and management in children.
@en
type
label
Hydroxyurea for the treatment ...... y, and management in children.
@ast
Hydroxyurea for the treatment ...... y, and management in children.
@en
prefLabel
Hydroxyurea for the treatment ...... y, and management in children.
@ast
Hydroxyurea for the treatment ...... y, and management in children.
@en
P2860
P356
P1476
Hydroxyurea for the treatment ...... ty, and management in children
@en
P2093
John J Strouse
P2860
P304
P356
10.1002/PBC.24178
P577
2012-04-19T00:00:00Z